Allogene Therapeutics (NASDAQ:ALLO) Releases Quarterly Earnings Results, Beats Expectations By $0.04 EPS

Allogene Therapeutics (NASDAQ:ALLO) issued its quarterly earnings data on Wednesday. The company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.04, FiscalAI reports. The company had revenue of $4.64 million for the quarter, compared to analysts’ expectations of $0.00 million.

Here are the key takeaways from Allogene Therapeutics’ conference call:

• Allogene expanded the ALPHA3 trial to more than 80 active sites ahead of schedule and now expects approximately 100 sites by year-end, supporting enrollment and broader community access to cema-cel.
• Cema-cel received FDA RMAT and Fast Track designations for first-line consolidation in MRD-positive large B-cell lymphoma, which Allogene views as validation of the unmet need and the ALPHA3 approach.
• ALPHA3’s interim EFS analysis remains expected around mid-2027 despite faster site activation; management said statistical significance at the interim point would require overwhelming efficacy.
• ALLO-316 showed a 31% confirmed response rate in CD70-high renal cell carcinoma, with durable responses among five responders, but management acknowledged the small dataset and significant safety challenges.
• Enrollment in the ALLO-329 RESOLUTION autoimmune disease trial is proceeding rapidly, with clinical and translational data—including safety, efficacy, and dose-cohort findings—expected in the fourth quarter of 2026.

Allogene Therapeutics Stock Down 2.4%

NASDAQ:ALLO traded down $0.05 during trading hours on Wednesday, reaching $2.07. 4,566,429 shares of the company’s stock were exchanged, compared to its average volume of 8,252,555. Allogene Therapeutics has a 1-year low of $0.99 and a 1-year high of $4.46. The firm has a market capitalization of $714.47 million, a price-to-earnings ratio of -2.69 and a beta of 0.48. The company has a 50-day moving average of $1.95 and a 200 day moving average of $2.11.

Institutional Investors Weigh In On Allogene Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Mercer Global Advisors Inc. ADV increased its holdings in shares of Allogene Therapeutics by 23.0% in the fourth quarter. Mercer Global Advisors Inc. ADV now owns 29,512 shares of the company’s stock valued at $40,000 after purchasing an additional 5,514 shares during the period. Russell Investments Group Ltd. grew its position in Allogene Therapeutics by 83.3% in the 4th quarter. Russell Investments Group Ltd. now owns 40,041 shares of the company’s stock valued at $55,000 after buying an additional 18,197 shares during the last quarter. Captrust Financial Advisors grew its position in Allogene Therapeutics by 237.9% in the 4th quarter. Captrust Financial Advisors now owns 53,101 shares of the company’s stock valued at $73,000 after buying an additional 37,386 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its stake in Allogene Therapeutics by 28.2% in the 4th quarter. CANADA LIFE ASSURANCE Co now owns 50,951 shares of the company’s stock valued at $69,000 after buying an additional 11,221 shares during the period. Finally, Smartleaf Asset Management LLC purchased a new position in Allogene Therapeutics during the 4th quarter worth $38,000. 83.63% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

ALLO has been the topic of several research analyst reports. JPMorgan Chase & Co. upgraded shares of Allogene Therapeutics from an “underweight” rating to a “neutral” rating in a research note on Thursday, April 16th. Sanford C. Bernstein raised their price objective on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a report on Tuesday, April 14th. Argus lifted their target price on Allogene Therapeutics from $1.60 to $3.85 and gave the stock a “market perform” rating in a research report on Tuesday, April 14th. Citigroup reissued an “outperform” rating on shares of Allogene Therapeutics in a report on Tuesday, April 14th. Finally, Citizens Jmp upped their target price on Allogene Therapeutics from $5.00 to $8.00 and gave the company a “market outperform” rating in a research report on Tuesday, April 14th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Allogene Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $8.52.

About Allogene Therapeutics

Allogene Therapeutics is a clinical-stage biotechnology company focused on developing allogeneic, or “off-the-shelf,” chimeric antigen receptor T-cell (CAR T) therapies to treat a range of hematologic malignancies and solid tumors. The company leverages gene-editing technologies to generate universally compatible engineered T cells, aiming to overcome the limitations of patient-specific CAR T approaches such as manufacturing delays, variable product quality and treatment resistance.

The company’s pipeline includes multiple allogeneic CAR T candidates targeting key antigens in blood cancers.